After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven different scenarios: Pregnancy, breastfeeding, pediatrics, malignancy, tuberculosis ...